Category survey

Boosting lysosome function as a therapy for Alzheimer´s disease

Boosting lysosome function as a therapy for Alzheimer´s disease Investments < €500k Switzerland 2016

The Structure of Prionoid Tau Strains

The Structure of Prionoid Tau Strains Investments < €500k Switzerland 2016

Using uncoupling in mitochondria of astrocytes to promote neuroprotection in Alzheimer’s disease

Using uncoupling in mitochondria of astrocytes to promote neuroprotection in Alzheimer’s disease Investments < €500k Switzerland 2016

Imaging corticostriatal loop dysfunction during skilled locomotion of Parkinsonian mice

Imaging corticostriatal loop dysfunction during skilled locomotion of Parkinsonian mice Investments < €500k Switzerland 2016

The factor XII-driven contact system as a new therapeutic target in Alzheimer’s disease

The factor XII-driven contact system as a new therapeutic target in Alzheimer’s disease Investments < €500k Switzerland 2016

New ocular biomarkers for early detection of Alzheimer’s disease

New ocular biomarkers for early detection of Alzheimer’s disease Investments < €500k Switzerland 2016

Machine Learning Methods in Parkinson’s Disease Examination

Machine Learning Methods in Parkinson’s Disease Examination Investments < €500k Turkey 2016

The Role of Brain Extracellular Matrix in Neurodegeneration in Alzheimer’s Disease

The Role of Brain Extracellular Matrix in Neurodegeneration in Alzheimer’s Disease Investments < €500k Turkey 2016

Use of Phenoxazine Compounds in Alzheimer’s Disease Treatment

Use of Phenoxazine Compounds in Alzheimer’s Disease Treatment Investments < €500k Turkey 2016

Deep Brain Stimulation and MR Analysis in Parkinson’s Patients

Deep Brain Stimulation and MR Analysis in Parkinson’s Patients Investments < €500k Turkey 2016

Construction of Amyloid Protein Based Bacterial Biofilms via Synthetic Biology

Construction of Amyloid Protein Based Bacterial Biofilms via Synthetic Biology Investments < €500k Turkey 2016

Determination of the Change in Mitochondria Numbers in Lymphocytes of Alzheimer’s Patients via Quantitative in situ Mitochondrial Analysis

Determination of the Change in Mitochondria Numbers in Lymphocytes of Alzheimer’s Patients via Quantitative in situ Mitochondrial Analysis Investments < €500k Turkey 2016

Molecular Modeling and Synthesis of 2-Pyrazoline Derivatives for Alzheimer’s Disease Theraphy

Molecular Modeling and Synthesis of 2-Pyrazoline Derivatives for Alzheimer’s Disease Theraphy Investments < €500k Turkey 2016

Att hindra forskridandet av Alzheimers och andra demenssjukdomar. To prevent the spread of Alzheimer’s and other dementia diseases

Att hindra forskridandet av Alzheimers och andra demenssjukdomar. To prevent the spread of Alzheimer’s and other dementia diseases Investments < €500k Sweden 2016

Framtagning och karaktärisering av en ny typ av kognitionsförstärkare. 69/5000 Did you mean: Framtagning och karaktärisering av en ny typ av kognition förstärkare Development and characterization of a new type of cognition enhancer

Framtagning och karaktärisering av en ny typ av kognitionsförstärkare. 69/5000 Did you mean: Framtagning och karaktärisering av en ny typ av kognition förstärkare Development and characterization of a new type of cognition enhancer Investments < €500k Sweden 2016

Novel biomarkers and brain imaging techniques for Alzheimer’s disease to improve early diagnosis and development of novel therapies

Novel biomarkers and brain imaging techniques for Alzheimer’s disease to improve early diagnosis and development of novel therapies Investments < €500k Sweden 2016

Friska äldre med plackpatologi – individer med risk för Alzheimers sjukdom? Healthy Elderly With Plaque Pathology – Individuals At Risk Of Alzheimer’s Disease?

Friska äldre med plackpatologi – individer med risk för Alzheimers sjukdom? Healthy Elderly With Plaque Pathology – Individuals At Risk Of Alzheimer’s Disease? Investments < €500k Sweden 2016

Multidomäna interventioner för att förebygga Alzheimers sjukdom: MIND-AD. Multidomain interventions to prevent Alzheimer’s disease: MIND-AD

Multidomäna interventioner för att förebygga Alzheimers sjukdom: MIND-AD. Multidomain interventions to prevent Alzheimer’s disease: MIND-AD Investments < €500k Sweden 2016

CONTROL AND MODULATION OF HIPPOCAMPAL OLM INTERNEURONS IN MEMORY FORMATION

CONTROL AND MODULATION OF HIPPOCAMPAL OLM INTERNEURONS IN MEMORY FORMATION Investments < €500k Sweden 2016

Nya PET- och ELISA-baserade biomarkörer för Alzheimers sjukdom

Nya PET- och ELISA-baserade biomarkörer för Alzheimers sjukdom Investments < €500k Sweden 2016

Molecular PET imaging of Tau in comparison with AD and non-AD dementia pathology

Molecular PET imaging of Tau in comparison with AD and non-AD dementia pathology Investments < €500k Sweden 2016

Sequestrins – New small protein drugs targeting neurodegenerative disorders

Sequestrins – New small protein drugs targeting neurodegenerative disorders Investments < €500k Sweden 2016

Abnormal brain networks as novel biomarkers of neurodegeneration

Abnormal brain networks as novel biomarkers of neurodegeneration Investments < €500k Sweden 2016

Novel modulators of Aβ42 synthesis and clearance The route towards primary prevention in AD

Novel modulators of Aβ42 synthesis and clearance The route towards primary prevention in AD Investments < €500k Sweden 2016

Pathways to Alzheimer’s disease

Pathways to Alzheimer’s disease Investments < €500k Sweden 2016

From knowledge base of the pathogenic astrocyte-motoneuron communication in amyotrophic lateral sclerosis to therapeutic approaches

From knowledge base of the pathogenic astrocyte-motoneuron communication in amyotrophic lateral sclerosis to therapeutic approaches Investments < €500k Switzerland 2016

Dissecting the neuroprotective role of neurosteroids in Alzheimer’s disease: Modulation of bioenergetics and amyloid-ß/tau toxicity

Dissecting the neuroprotective role of neurosteroids in Alzheimer’s disease: Modulation of bioenergetics and amyloid-ß/tau toxicity Investments < €500k Switzerland 2016

Towards deciphering the role of N-terminal post-translational modifications in regulating the function of Huntingtin (Htt) in health and disease

Towards deciphering the role of N-terminal post-translational modifications in regulating the function of Huntingtin (Htt) in health and disease Investments < €500k Switzerland 2016

Structural and functional roles of exosomal nanovesicles in the formation, release and synaptotoxicity of amyloid proteins

Structural and functional roles of exosomal nanovesicles in the formation, release and synaptotoxicity of amyloid proteins Investments < €500k Switzerland 2016

Role of beta-secretase cleavage of non-amyloid substrates in Alzheimer`s Disease

Role of beta-secretase cleavage of non-amyloid substrates in Alzheimer`s Disease Investments < €500k Switzerland 2016

Novel ways for improved cell replacement strategies in Parkinsons disease: The potential of Nogo-A neutralization.

Novel ways for improved cell replacement strategies in Parkinsons disease: The potential of Nogo-A neutralization. Investments < €500k Switzerland 2016

Oxytocin as a key factor in the behavioral and psychological symptoms of Alzheimer’s disease

Oxytocin as a key factor in the behavioral and psychological symptoms of Alzheimer’s disease Investments < €500k Switzerland 2016

Development of a composite imaging/ gait-behaviour biomarker for early detection of cognitive impairment in ageing

Development of a composite imaging/ gait-behaviour biomarker for early detection of cognitive impairment in ageing Investments < €500k Switzerland 2016

The aging population: Does the increasing length of life result in more or less ill health?

The aging population: Does the increasing length of life result in more or less ill health? Investments < €500k Sweden 2016

A person-centred multidimensional interdisciplinary rehabilitation program for community dwelling older people with dementia and their informal primary caregivers: a randomised controlled trial

A person-centred multidimensional interdisciplinary rehabilitation program for community dwelling older people with dementia and their informal primary caregivers: a randomised controlled trial Investments < €500k Sweden 2016

Ageing: an innovative and TECHnology-enriched HOME care support for older patients with Alzheimer’s Disease. The TECH@HOME randomized trial

Ageing: an innovative and TECHnology-enriched HOME care support for older patients with Alzheimer’s Disease. The TECH@HOME randomized trial Investments < €500k Sweden 2016

Finding the right words in neurogenic communication disorders: Naming of objects and actions, communicative strategies in conversation and effects of training.

Finding the right words in neurogenic communication disorders: Naming of objects and actions, communicative strategies in conversation and effects of training. Investments < €500k Sweden 2016

The Genetics of ALS and related Neurodegenerative Syndromes: Finding the Genes.

The Genetics of ALS and related Neurodegenerative Syndromes: Finding the Genes. Investments < €500k Sweden 2016

Diagnostik av Alzheimers sjukdom: lösligt amyloid-beta med PET-kamera. Diagnosis of Alzheimer’s Disease: Soluble Amyloid Beta with PET Camera

Diagnostik av Alzheimers sjukdom: lösligt amyloid-beta med PET-kamera. Diagnosis of Alzheimer’s Disease: Soluble Amyloid Beta with PET Camera Investments < €500k Sweden 2016

Studies on the senescent human noradrenergic system with the novel iDISCO 3D immuno-imaging method with special attention on Alzheimer’s disease

Studies on the senescent human noradrenergic system with the novel iDISCO 3D immuno-imaging method with special attention on Alzheimer’s disease Investments < €500k Sweden 2016

Oxysteroler och neurodegeneration. Oxysterols and neurodegeneration

Oxysteroler och neurodegeneration. Oxysterols and neurodegeneration Investments < €500k Sweden 2016